Autologous serum therapy in recalcitrant laser-assisted in situ keratomileusis-induced neurotrophic epitheliopathy  by Lin, Shan-Jiun et al.
lable at ScienceDirect
Taiwan Journal of Ophthalmology 5 (2015) 109e113Contents lists avaiTaiwan Journal of Ophthalmology
journal homepage: www.e-t jo.comOriginal articleAutologous serum therapy in recalcitrant laser-assisted in situ
keratomileusis-induced neurotrophic epitheliopathy
Shan-Jiun Lin a, Chien-Chia Su a, David C.K. Chang b, Brian Hsi a, Fung-Rong Hu a,
Shwu-Huey Lee c, **, I-Jong Wang a, d, *
a Department of Ophthalmology, National Taiwan University Hospital, Taipei, Taiwan
b Nobel Eye Clinic, Taipei, Taiwan
c Department of Ophthalmology, Cathay General Hospital, Taipei, Taiwan
d Institute of Clinical Medicine, China Medical University, Taichung, Taiwana r t i c l e i n f o
Article history:
Received 9 March 2015
Received in revised form
11 May 2015
Accepted 20 May 2015




LASIK-induced neurotrophic epitheliopathyConﬂicts of interest: The authors declare that they h
* Corresponding author. Department of Ophthalm
versity Hospital, 7, Chung-Shan South Road, Taipei, Ta
** Corresponding author. Department of Ophthalmol
280 Renai Rd. Sec.4, Taipei, Taiwan.
E-mail addresses: shwuhuey@ms14.hinet.net (S.-
(I.-J. Wang).
http://dx.doi.org/10.1016/j.tjo.2015.05.004
2211-5056/Copyright © 2015, The Ophthalmologic Soa b s t r a c t
Background/Purpose: To evaluate the efﬁcacy of autologous serum eye drops for patients with recalci-
trant laser-assisted in situ keratomileusis (LASIK)-induced neurotrophic epitheliopathy (LINE) unre-
sponsive to conventional treatment, and to determine the possible predisposing risk factors of these
patients.
Methods: We enrolled 10 consecutive patients (20 eyes) undergoing femtosecond-assisted myopic LASIK
surgery presenting with recalcitrant LINE for > 1 year. Another 340 patients (713 eyes) receiving
femtosecond-assisted myopic LASIK without recalcitrant LINE were set as controls. Possible risk factors
associated with recalcitrant LINE were investigated. Twenty percent autologous serum treatment was
prescribed to 20 eyes. The efﬁcacy of autologous serumwas assessed with ocular surface conditions, tear
function, and the change of best-corrected visual acuity.
Results: Age older than 30 years [odds ratio (OR) ¼ 7.74; 95% conﬁdence interval (CI), 1.74e34.50], ﬂap
thickness < 110 mm (OR ¼ 3.47; 95% CI, 1.22e9.73), and a ﬂap diameter < 8.5 mm (OR ¼ 5.38; 95% CI, 1.95
e14.85) pose higher risks in femtosecond laser-assisted myopic LASIK. All eyes (100%) achieved remis-
sion after autologous serum treatment. The visual acuity before treatment was 0.49 ± 0.41 in LogMAR,
and the visual acuity after treatment was 0.14 ± 0.22 in LogMAR. Time to achieve remission was
8.26 ± 11.87 weeks. Mean relapse-free survival after discontinuing autologous serum was 47 weeks.
Conclusion: Risk factors of recalcitrant LINE in femtosecond laser-assisted myopic LASIK were identiﬁed
as older age, a thinner ﬂap (<110 mm), and a small ﬂap diameter (<8.5 mm). Autologous serum eye drops
can effectively improve corneal surface conditions and postoperative visual acuity.
Copyright © 2015, The Ophthalmologic Society of Taiwan. Published by Elsevier Taiwan LLC. All rights
reserved.1. Introduction
Laser-assisted in situ keratomileusis (LASIK) is the most per-
formed procedure for treating refractive errors.1 For both micro-
keratome- or femtosecond-assisted LASIK, the standard procedureave no competing interests.
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ciety of Taiwan. Published by Elsevincludes the creation of a ﬂapwith intact epithelium and ablation of
the stromal surface with excimer laser keratomileusis. However,
the creation of corneal ﬂaps inevitably damages the nerve ﬁbers
within the ﬂap, interrupting the cornea-trigeminal nerve-brain-
stem-facial nerve-lacrimal gland reﬂex arc which inﬂuences both
basal and stimulated tear secretion and drives the blinking mech-
anism.2 Occasionally, such interruptionwill result in LASIK-induced
neurotrophic epitheliopathy (LINE).3,4
LINE always presents as a dry eye-like syndrome, which leads to
the breakdown of the corneal epithelium a few days to weeks after
surgery, and signiﬁcantly impacts clinical outcomes and satisfac-
tion.3,4 Multiple risk factors have been implicated in LINE, including
decreased neurotrophic factors to epithelial cells, reduced blinkingier Taiwan LLC. All rights reserved.
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distribution, more evaporative tear loss, and possible damage to
limbal goblet cells by the microkeratome suction ring.4 Among
these factors, the components in tears, including the neurotrophic
factors that help nerve regeneration, epidermal growth factor, and
vitamin A, play important roles in normal epithelialization.5 When
these components are depleted, epithelialization is impaired,
leading to epithelial break down. According to its pathophysiology,
it is reasonable to treat LINE with autologous serum.5 Autologous
serum was reported to be beneﬁcial in keratoconjunctivitis sicca
and persistent epithelial defects.6,7 Matsumoto et al3 demonstrated
the promising effect of 20% autologous serum for the restoration of
the ocular surface epithelial integrity in patients with neurotrophic
keratopathy. Autologous serum harbors essential elements in the
ocular surface: (1) neurotrophic mediators, such as insulin-like
growth factor 1, nerve growth factor, and substance P; (2) compo-
nents maintaining healthy epithelium, including epidermal growth
factor, transforming growth factors (TGFs), and vitamin A3,5; and
(3) anti-inﬂammatory factors and matrix metalloproteinase in-
hibitors, which can promote a greater epithelial healing rate.3,5
Conventional treatments, such as artiﬁcial tears, alleviate tear
insufﬁciency and solve most cases of LINE. However, recalcitrant
cases with prolonged nerve regeneration exhibit a poor clinical
response to conventional treatments and may beneﬁt from essen-
tial elements of autologous serum. Herein, the purpose of this study
is to investigate the predisposing risk factors of recalcitrant LINE
and to evaluate the efﬁcacy of autologous serum eye drops for
patients with recalcitrant LINE.
2. Methods
2.1. Patients
We performed a retrospective review of 10 consecutive patients
who visited the outpatient clinic at the Department of Ophthal-
mology, National Taiwan University Hospital, Taipei, Taiwan from
January 2008 to May 2012. All 10 patients (20 eyes) with previous
myopic LASIK surgery had recalcitrant LINE for > 1 year and failed
to respond to conventional treatments such as artiﬁcial tears or
punctal occlusion as described previously.4 External eye conditions
such as punctate keratitis and epithelial defects were documented
with photography in every case as part of our daily practice (Fig. 1).
Decreased corneal sensitivity was conﬁrmed with quantitated
corneal sensation measurement utilizing the Cochet-Bonnet
esthesiometer. All patients were referred to our hospital by one
local clinic (Nobel Eye Clinic, Taipei, Taiwan). Another 340 patients
who received LASIK surgery in the same clinic without recalcitrant
LINE were selected as the control group. There were 713 eyes, in
which 33 eyes were retreated once. The eligible inclusion criteria
included patients without presentations of LINE after surgery >1
year later and patients with a diagnosis of LINE improved with
conventional treatments. Patients presenting systemic or ocular
conditions that could interfere with ocular surface status were
excluded. The research protocol was approved by the Human
Research and Ethics Committee of the National Taiwan University
Hospital, and informed consent for participation in the study was
obtained from participants. Research carried out was in compliance
with the Helsinki Declaration.
2.2. Preparation of autologous serum eye drops
Brieﬂy, autologous serum was prepared from 30 mL of blood
taken using venipuncture and centrifuged for 6 minutes at 3207 g
in sterilized tubes. The separated serumwas ﬁltered and extracted.
TwomL of serumwere allocated to 10mL bottles and diluted to 20%concentration by adding 8 mL sterile saline solution to each bottle.
Six bottles were made at one time. Patients were instructed to keep
the currently used bottle <4C and other unused bottles <20C.
The bottles were discarded if stored for >7 days.3
2.3. Examinations
The severity of neurotrophic epitheliopathy was evaluated and
recorded from two aspects: poor ocular surface condition and tear
dysfunction. Ocular surface conditions such as inﬂammation,
ﬂuorescein, and rose bengal staining on conjunctiva and cornea,
and re-epithelialization were featured. All patients visited our
outpatient clinic biweekly until re-epithelialization of the cornea
without ﬂuorescein stain had occurred. Tear function evaluations
were incorporated into tear break-up time test, tear meniscus
height, and Schirmer's test 1 with anesthesia at the ﬁrst visit before
treatment in all cases.
The pretreatment visual acuity was measured at the initial visit.
The post-treatment visual acuity was recorded 2e4 weeks after
autologous serum treatment. The efﬁcacy of the autologous serum
was evaluated by healing of neurotrophic epitheliopathy and the
improvement of visual acuity in logMAR. The investigated factors
associated with recalcitrant LINE included age, gender, the value of
basal Schirmer's test, and spherical equivalent refraction (SER)
correction in LASIK, ﬂap size, and ﬂap thickness. All eyes received
myopic LASIK with femtosecond laser-created ﬂaps (IntraLase;
IntraLase Corp/Advanced Medical Optics Inc., Santa Anna, CA, USA).
2.4. Statistical analysis
To examine the signiﬁcance of the investigated factors predis-
posing to neurotrophic epitheliopathy, binary logistic regression
was examined to further verify the correlations of Schirmer's test,
SER, ﬂap size, and ﬂap thickness documented before LASIK surgery
with LINE. Remission of recalcitrant LINE was deﬁned as complete
re-epithelialization without ﬂuorescein staining of the cornea.
Once patients obtained remission, autologous serum was dis-
continued and shifted to conventional treatment. KaplaneMeier
survival curve for relapse of LINE was calculated in patients
obtaining remission status. All statistical analyses were conducted
using SPSS statistics 17.0 (SPSS Inc., Chicago, IL, USA). A p value
<0.05 was considered statistically signiﬁcant.
3. Results
Multiple factors were investigated for their association with
recalcitrant LINE: age, gender, tear function, and SER documented
before LASIK surgery, ﬂap size, and ﬂap thickness. Table 1 demon-
strates the basic characteristics of patients with recalcitrant LINE
and patients without recalcitrant LINE. The logistic regression
model assumes that the effects of the risk factors are multiplicative.
The effect of each risk factor is expressed as an odds ratio (OR) for
the development of recalcitrant LINE. According to themodel, older
patients (age > 30 years) were more vulnerable to recalcitrant LINE
than young patients (age < 30 years), with an OR of 7.74 [95%
conﬁdence interval (CI), 1.74e34.50]. Femtosecond-created ﬂaps
with a thickness of 95e109 mmwere more in danger than a thicker
ﬂap (110e130 mm), with an OR of 3.47 (95% CI, 1.22e9.73). A small
ﬂap diameter (8e8.4 mm) was also at higher risk than large ﬂaps
(8.5e9 mm), with an OR of 5.38 (95% CI, 1.95e14.85). Table 2 dis-
plays multivariate logistic regression of the possible factors corre-
lated with recalcitrant LINE.
Autologous serum eye drops were prescribed for 20 eyes of 10
patients with recalcitrant LINE. The pretreatment visual acuity was
0.49 ± 0.41 LogMAR units, and the post-treatment visual acuity was
Fig. 1. External photography of one case with bilateral recalcitrant laser-assisted in situ keratomileusis-induced neurotrophic epitheliopathy External photography shows low tear
meniscus and a classic ﬂuorescein staining pattern with nearly conﬂuent punctate epithelial erosions on over the laser-assisted in situ keratomileusis ﬂap on (A) right eye and (B)
left eye.
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0.35 ± 0.33 LogMAR units. All eyes (100%) achieved remission after
autologous serum treatment. Time to achieve remission was
8.26 ± 11.87 weeks. Eleven eyes (55%) received autologous serum
treatment more than once. KaplaneMeier survival curve analysis of
LINE relapse after discontinuing autologous serum is illustrated in
Fig. 2. Mean relapse-free survival was 47 weeks, and relapse-free
probabilities at 10 weeks, 34 weeks, and 41 weeks were 86%, 78%,
and 58%, respectively. The Schirmer's test value before treatment
was 7.00 ± 3.77 mm, and the Schirmer's test value after treatment
was 7.05 ± 2.38 mm.Table 1
Basic characteristics of patients with recalcitrant LINE and patients without re
With recalcitrant LINE (n
Gender (Female/male) 16/4
Age (y) 36.7 ± 4.96
Before LASIK
Schirmer's test (mm) 7.00 ± 3.77
SER 7.12 ± 2.16
Flap size (mm) 8.45 ± 0.56
Flap thickness (mm) 103.50 ± 10.53
LASIK ¼ laser-assisted in situ keratomileusis; LINE ¼ laser-assisted in situ
SER ¼ spherical equivalent refraction.4. Discussion
Post-LASIK tear dysfunction and dysesthesia syndrome is a
spectrum of disease characterized as transient or persistent post-
operative neurotrophic disease due to corneal denervation. Tran-
section of the sub-basal nerve plexus and deep stromal nerve
during ﬂap creation are contributory to the main pathophysiology.8
Although corneal sensation can return to normal value fromweeks
to months,4 sub-basal nerve ﬁber density has been reported not to
return to preoperative levels by 2 years in confocal microscopy
studies.9 Prolonged corneal nerve regeneration is to blame incalcitrant LINE.







keratomileusis-induced neurotrophic epitheliopathy; n ¼ eye number;
Table 2
Multivariate logistic regression of the possible factors correlated with recalcitrant LINE.
Factors Odds ratio 95% Conﬁdence interval p
Age (y)
 30 1
> 30 7.74 1.74e34.50 0.007
Gender
Female 1
Male 0.76 0.23e2.59 0.662
Schirmer's test before LASIK (mm) 0.98 0.88e1.09 0.668
SER (diopter) 0.80 0.62e1.04 0.094
Flap-thickness (mm)
110e130 1
95e109 3.47 1.22e9.73 0.02
Flap-diameter (mm)
8.5e9 1
8e8.4 5.38 1.95e14.85 0.001
LASIK ¼ laser-assisted in situ keratomileusis; SER ¼ spherical equivalent refraction.
Bold represents signiﬁcant values.
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and ﬂap characteristics, have been proposed but remained incon-
clusive in nerve regeneration after LSAIK. In this study, we found
that patients older than 30 years, ﬂap thickness <110 mm, and a ﬂap
diameter <8.5 mm pose higher risks in femtosecond laser-assisted
myopic LASIK.
Several preoperative risk factors have been proposed, including
Schirmer's test score, long-term contact lens wear, age, and female
gender. Aging and female gender have both been found as risk
factors in dry eye syndrome, but remained inconclusive in post-
LASIK tear dysfunction.10e12 In our study, older age was a risk fac-
tor in the development of recalcitrant LINE, especially in those older
than 30 years. Female gender comprised 76% of patients receiving
myopic LASIK in this study, but was not a risk factor in recalcitrant
LINE. Some studies found that lower preoperative Schirmer scores
are associated with tear dysfunction after LASIK. However, these
studies focused on dry eye symptoms within 1 year.12,13 Preopera-
tive Schirmer's test value was not related to poor nerve regenera-
tion after 1 year and recalcitrant LINE in this study.
Whether a thinner ﬂap results in less postoperative neuropathic
disease is hotly debated. Salom~ao and Wilson14 found that ﬂapsFig. 2. KaplaneMeier survival curve of laser-assisted in situ keratomileusis-induced
neurotrophic epitheliopathy relapse after discontinuing autologous serum. Mean
relapse-free survival was 47 weeks, and relapse-free probabilities at 10 weeks, 34
weeks, and 41 weeks were 86%, 78%, and 58%, respectively.performed with a microkeratome (180 mm) had a signiﬁcantly
higher incidence of LINE, compared with femtosecond created ﬂaps
(110e120 mm). Conversely, Patel et al15 showed that sub-basal
nerve density and corneal sensitivity were similar in ﬂaps created
with microkeratome (180 mm) and femtosecond (120 mm) at any
examination. In our study, all cases received ﬂaps with femto-
second creation. We found those with a ﬂap thickness <110 mm
carry a signiﬁcantly higher risk for the development of recalcitrant
LINE than ﬂaps between 110 mm and 130 mm (p ¼ 0.02), implying
slower nerve regeneration in this subgroup. Photodisruption of
femtosecond laser at the level of Bowman's layers may be
responsible for this phenomenon.
Flap hinge and its inﬂuence on corneal nerve damage during
LASIK is also of interest. Muller et al2 portrayed the main trunk of
nerve entering the cornea at the 3 o'clock and 9 o'clock positions,
then spreading centrally and anteriorly. They suggested a superi-
orly hinged corneal ﬂap can transect less major corneal innervation
than nasally hinged ﬂap.16,17 However, other studies illustrated
nerve bundles entering the cornea at all directions.18e20 The results
of hinge positions and post-LASIK tear dysfunction were still con-
ﬂicting. Larger hinge width was hypothesized to reserve more
nerve bundle and reduce postoperative tear dysfunction.21 All our
cases received superiorly hinged ﬂaps. Smaller ﬂap diameter was
correlated with smaller hinge width, and thus a higher risk of
recalcitrant LINE, which was consistent with previous studies.
Loss of trophic inﬂuence on corneal epithelium and prolonged
tear insufﬁciency as a consequence of poor reinnervation after
LASIK results in ocular surface changes, namely LINE. Conventional
treatments, such as artiﬁcial tears or punctal occlusion, alleviate
tear insufﬁciency and solve most cases of LINE. However, for those
intractable cases, trophic factors play a more important role in
rebuilding healthy corneal epithelium. The effectiveness of autol-
ogous serum has been reported in the prolongation of the tear
break up time and a reduction in rose bengal staining score 1
month, 3 months, and 6 months after LASIK.22 In this study, we
evaluated the efﬁcacy of autologous serum treatment in patients
with recalcitrant LINE with ocular surface condition and tear
function. We opted for 20% autologous serum eye drops instead of
other concentrations that were previously used in literature23,24
based on the concentration of TGF-beta in tears. TGF-beta, which
is believed to inhibit epithelial proliferation, is around ﬁve times
higher in concentration in human serum than in tear.25 In our
study, all of the eyes had remission to clear cornea after autologous
serum treatment. The best corrected visual acuity also improved
after the treatment of autologous serum. The increased corneal
surface regularity and decreased epitheliopathy may have
S.-J. Lin et al. / Taiwan Journal of Ophthalmology 5 (2015) 109e113 113contributed to the visual improvement. Schirmer's test failed to
reach statistical signiﬁcance after treatment due to a small number
of cases. In summary, our results indicated the efﬁcacy of autolo-
gous serum treatment for recalcitrant LINE patients. Autologous
serum therapy was effective in the treatment of neurotrophic epi-
theliopathy compared with conventional treatment. None of our
patients showed any ocular complications under careful prepara-
tion and storage of autologous serum eye drops.
In conclusion, risk factors of recalcitrant LINE in femtosecond
laser-assisted myopic LASIK were identiﬁed as older age, a thinner
ﬂap (<110 mm), and a small ﬂap diameter (<8.5 mm). Patients with
recalcitrant LINE unresponsive to conventional treatment may
beneﬁt from autologous serum eye drops, which effectively
improve corneal surface conditions and postoperative visual acuity.
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